June 15, 2020 / 4:20 PM / a month ago

Novavax to raise $200 million through stock offering to fund COVID-19 vaccine

(Reuters) - Novavax Inc said on Monday it would raise fresh capital through a $200 million preferred stock offering as it races to develop a vaccine for the new coronavirus, sending its shares up 10.5%.

The private placement to investment fund RA Capital Management was priced at par with Novavax’s Friday closing price.

The stock deal is in addition to a $60 million funding from the U.S. Department of Defense to fund the manufacturing of the company’s experimental COVID-19 vaccine.

Maryland-based Novavax began testing its coronavirus vaccine candidate in humans in May, with a target of producing over a billion doses of its vaccine candidate next year.

The company had $244.7 million in cash and cash equivalents as of March 31.

Novavax shares were trading at $50.34.

Reporting by Shivani Singh in Bengaluru; Editing by Shounak Dasgupta

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below